Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Gemcitabine and Cisplatin for Bladder Sparing in MIBC
NCT05401279Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in muscle-invasive bladder cancer (MIBC), sponsored by Renji Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05401279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05401279.